Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial

Peter Gimsing; Kristina Carlson; Ingemar Turesson; Peter Fayers; Anders Waage; Annette Vangsted; Anne Mylin; Christian Gluud; Gunnar Juliusson; Henrik Gregersen; Henrik Hjorth-Hansen; Ingerid Nesthus; Inger Marie Dahl Bahn; Jan Westin; Johan Lanng Nielsen; Lene Meldgaard Knudsen; Lucia Ahlberg; Martin Hjorth; Niels Abildgaard; Niels Frost Andersen; Olle Linder; Finn Wisløff

doi:10.1016/S1470-2045(10)70198-4

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial

Peter Gimsing, Kristina Carlson, Ingemar Turesson, Peter Fayers, Anders Waage, Annette Vangsted, Anne Mylin, Christian Gluud, Gunnar Juliusson, Henrik Gregersen, Henrik Hjorth-Hansen, Ingerid Nesthus, Inger Marie Dahl Bahn, Jan Westin, Johan Lanng Nielsen, Lene Meldgaard Knudsen, Lucia Ahlberg, Martin Hjorth, Niels Abildgaard, Niels Frost AndersenOlle Linder, Finn Wisløff

Research output: Contribution to journal › Journal article › Research › peer-review

108 Citations (Scopus)

Abstract

Compared with placebo, prophylactic treatment with bisphosphonates reduces risk of skeletal events in patients with multiple myeloma. However, because of toxicity associated with long-term bisphosphonate treatment, establishing the lowest effective dose is important. This study compared the effect of two doses of pamidronate on health-related quality of life and skeletal morbidity in patients with newly diagnosed multiple myeloma.

Original language	English
Journal	Lancet Oncology
Volume	11
Issue number	10
Pages (from-to)	973-82
Number of pages	10
ISSN	1470-2045
DOIs	https://doi.org/10.1016/S1470-2045(10)70198-4
Publication status	Published - 1 Oct 2010

Access to Document

10.1016/S1470-2045(10)70198-4

Library access?

Check availability at the Royal Danish Library

Cite this

Gimsing, P., Carlson, K., Turesson, I., Fayers, P., Waage, A., Vangsted, A., Mylin, A., Gluud, C., Juliusson, G., Gregersen, H., Hjorth-Hansen, H., Nesthus, I., Bahn, I. M. D., Westin, J., Nielsen, J. L., Meldgaard Knudsen, L., Ahlberg, L., Hjorth, M., Abildgaard, N., ... Wisløff, F. (2010). Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncology, 11(10), 973-82. https://doi.org/10.1016/S1470-2045(10)70198-4

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. / Gimsing, Peter; Carlson, Kristina; Turesson, Ingemar et al.
In: Lancet Oncology, Vol. 11, No. 10, 01.10.2010, p. 973-82.

Research output: Contribution to journal › Journal article › Research › peer-review

Gimsing, P, Carlson, K, Turesson, I, Fayers, P, Waage, A, Vangsted, A, Mylin, A, Gluud, C, Juliusson, G, Gregersen, H, Hjorth-Hansen, H, Nesthus, I, Bahn, IMD, Westin, J, Nielsen, JL, Meldgaard Knudsen, L, Ahlberg, L, Hjorth, M, Abildgaard, N, Andersen, NF, Linder, O & Wisløff, F 2010, 'Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial', Lancet Oncology, vol. 11, no. 10, pp. 973-82. https://doi.org/10.1016/S1470-2045(10)70198-4

@article{82187d4007a4443abd33ee334820e40a,

title = "Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial",

abstract = "Compared with placebo, prophylactic treatment with bisphosphonates reduces risk of skeletal events in patients with multiple myeloma. However, because of toxicity associated with long-term bisphosphonate treatment, establishing the lowest effective dose is important. This study compared the effect of two doses of pamidronate on health-related quality of life and skeletal morbidity in patients with newly diagnosed multiple myeloma.",

author = "Peter Gimsing and Kristina Carlson and Ingemar Turesson and Peter Fayers and Anders Waage and Annette Vangsted and Anne Mylin and Christian Gluud and Gunnar Juliusson and Henrik Gregersen and Henrik Hjorth-Hansen and Ingerid Nesthus and Bahn, {Inger Marie Dahl} and Jan Westin and Nielsen, {Johan Lanng} and {Meldgaard Knudsen}, Lene and Lucia Ahlberg and Martin Hjorth and Niels Abildgaard and Andersen, {Niels Frost} and Olle Linder and Finn Wisl{\o}ff",

year = "2010",

month = oct,

day = "1",

doi = "10.1016/S1470-2045(10)70198-4",

language = "English",

volume = "11",

pages = "973--82",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "TheLancet Publishing Group",

number = "10",

}

TY - JOUR

T1 - Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial

AU - Gimsing, Peter

AU - Carlson, Kristina

AU - Turesson, Ingemar

AU - Fayers, Peter

AU - Waage, Anders

AU - Vangsted, Annette

AU - Mylin, Anne

AU - Gluud, Christian

AU - Juliusson, Gunnar

AU - Gregersen, Henrik

AU - Hjorth-Hansen, Henrik

AU - Nesthus, Ingerid

AU - Bahn, Inger Marie Dahl

AU - Westin, Jan

AU - Nielsen, Johan Lanng

AU - Meldgaard Knudsen, Lene

AU - Ahlberg, Lucia

AU - Hjorth, Martin

AU - Abildgaard, Niels

AU - Andersen, Niels Frost

AU - Linder, Olle

AU - Wisløff, Finn

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Compared with placebo, prophylactic treatment with bisphosphonates reduces risk of skeletal events in patients with multiple myeloma. However, because of toxicity associated with long-term bisphosphonate treatment, establishing the lowest effective dose is important. This study compared the effect of two doses of pamidronate on health-related quality of life and skeletal morbidity in patients with newly diagnosed multiple myeloma.

AB - Compared with placebo, prophylactic treatment with bisphosphonates reduces risk of skeletal events in patients with multiple myeloma. However, because of toxicity associated with long-term bisphosphonate treatment, establishing the lowest effective dose is important. This study compared the effect of two doses of pamidronate on health-related quality of life and skeletal morbidity in patients with newly diagnosed multiple myeloma.

U2 - 10.1016/S1470-2045(10)70198-4

DO - 10.1016/S1470-2045(10)70198-4

M3 - Journal article

SN - 1470-2045

VL - 11

SP - 973

EP - 982

JO - Lancet Oncology

JF - Lancet Oncology

IS - 10

ER -